Cipla Limited
CIPLA.NS
₹1372.60
▲ 0.70%
Cipla bucked the weak pharma trend today, edging up 0.70% to ₹1,372.60 despite no specific news flow behind the move. The stock's medium-term performance has been under pressure, down 12.18% over one year and 8.27% over two years, though the longer-term trend remains positive with a 9.19% CAGR over a decade. A large analyst base of 36 brokerages continues to hold a consensus buy rating, with an average target of ₹1,509.08 sitting well above current levels.
CAGR Performance
| 1 Year | 2 Years | 5 Years | 10 Years |
|---|---|---|---|
| -12.18% | -8.27% | 7.66% | 9.19% |
Analyst Consensus
Average Target Price: ₹1509.08 (range ₹1170.00 - ₹1768.00) based on 36 analysts
Strong Buy: 8
Buy: 14
Hold: 10
Sell: 3
Strong Sell: 1
Related News
| Sep 3, 2026 | Cipla, Qilu Pharmaceutical Partner For Licensing, Supply Of Biosimilar To Keytruda In US |
No comments:
Post a Comment